Results · Apr-Jun 2026
Piramal Pharma Q1 FY27 results
Sales grew 17% to ₹2,270 crore from ₹1,934 crore in Apr-Jun 2025.
Operating profit grew 83% to ₹195 crore, an operating margin of 8.6% (up 3.1 points from a year ago).
The net loss narrowed to ₹69.4 crore from ₹81.7 crore.
Against Jan-Mar 2026: sales −18%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2,270 | 1,934 | +17% |
| Operating profit (EBITDA) | 195.2 | 106.7 | +83% |
| Operating margin | 8.6% | 5.5% | +3.1 pts |
| Net profit | -69.4 | -81.7 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.